The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food
Authors:
- Hans EricssonHEHans Ericsson
- Folke SjöbergFSFolke Sjöberg
- Maria HeijerMHMaria Heijer
- Hassan DoraniHDHassan Dorani
- Peter JohanssonPJPeter Johansson
- Maria WollbrattMWMaria Wollbratt
- Ensio NorjavaaraENEnsio Norjavaara
- 1 December 2012
- journal article
- clinical trial
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 98 (3) , 436-444
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyEuropean Heart Journal, 2011
- Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysisDiabetologia, 2010
- Assessing the potential of glucokinase activators in diabetes therapyNature Reviews Drug Discovery, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Diabetes Mellitus in German Primary Care: Quality of Glycaemic Control and Subpopulations not well Controlled – Results of the DETECT StudyExperimental and Clinical Endocrinology & Diabetes, 2008
- Glucokinase activators in diabetes managementExpert Opinion on Investigational Drugs, 2008
- Is Glycemic Control Improving in U.S. Adults?Diabetes Care, 2008
- New Drugs for Type 2 Diabetes MellitusDrugs, 2008
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999